Literature DB >> 10608859

Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice.

A Forlino1, F D Porter, E J Lee, H Westphal, J C Marini.   

Abstract

We utilized the Cre/lox recombination system to develop the first knock-in murine model for osteogenesis imperfecta (OI). The moderately severe OI phenotype was obtained from an alpha1(I) Gly(349) --> Cys substitution in type I collagen, reproducing the mutation in a type IV OI child. We introduced four single nucleotide (nt) changes into murine col1a1 exon 23: the disease causing G-->T transversion (nt 1546), an adjacent G-->T change (nt 1551) to generate a GUC ribozyme cleavage site, and two transversions (nt 1567 C-->A and nt 1569 C-->G) to cause a Leu --> Met substitution. We also introduced a 3.2-kilobase pair transcription/translation stop cassette in intron 22, flanked by directly repeating lox recombination sites. After homologous recombination in ES cells, two male chimeras were obtained. Chimeras were mated with transgenic females expressing Cre recombinase to remove the stop cassette from a portion of the progeny's cells. To generate mice with full expression of the Gly(349) --> Cys mutation, these offspring were then mated with wild-type females. Skeletal staining and bone histology of the F2 revealed a classical OI phenotype with deformity, fragility, osteoporosis and disorganized trabecular structure. We designate these mice BrtlIV (Brittle IV). BrtlIV mice have phenotypic variability ranging from perinatal lethality to long term survival with reproductive success. The phenotypic variability is not associated with differences in expression levels of the mutant allele in total RNA derived from tissue extracts. Expression of the mutant protein is also equivalent in different phenotypes. Thus, these mice are an excellent model for delineation of the modifying factors postulated to affect human OI phenotypes. In addition, we generated knock-in mice carrying an "intronic" inclusion by mating chimeras with wild-type females. Alternative splicing involving the stop cassette results in retention of non-collagenous sequences. These mice reproduce the lethal phenotype of similar human mutations and are designated BrtlII.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608859     DOI: 10.1074/jbc.274.53.37923

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.

Authors:  P A Dawson; J C Marini
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

2.  Role of genetic background in determining phenotypic severity throughout postnatal development and at peak bone mass in Col1a2 deficient mice (oim).

Authors:  Stephanie M Carleton; Daniel J McBride; William L Carson; Carolyn E Huntington; Kristin L Twenter; Kristin M Rolwes; Christopher T Winkelmann; J Steve Morris; Jeremy F Taylor; Charlotte L Phillips
Journal:  Bone       Date:  2008-01-05       Impact factor: 4.398

3.  Finite element analysis of bone strength in osteogenesis imperfecta.

Authors:  Peter Varga; Bettina M Willie; Chris Stephan; Kenneth M Kozloff; Philippe K Zysset
Journal:  Bone       Date:  2020-01-22       Impact factor: 4.398

Review 4.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

5.  Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect.

Authors:  Martin O Bergo; Bryant Gavino; Jed Ross; Walter K Schmidt; Christine Hong; Lonnie V Kendall; Andreas Mohr; Margarita Meta; Harry Genant; Yebin Jiang; Erik R Wisner; Nicholas Van Bruggen; Richard A D Carano; Susan Michaelis; Stephen M Griffey; Stephen G Young
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

6.  Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.

Authors:  Diana Olvera; Rachel Stolzenfeld; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2018-05-07       Impact factor: 6.741

7.  Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.

Authors:  B P Sinder; L E White; J D Salemi; M S Ominsky; M S Caird; J C Marini; K M Kozloff
Journal:  Osteoporos Int       Date:  2014-05-07       Impact factor: 4.507

8.  Differential response to intracellular stress in the skin from osteogenesis imperfecta Brtl mice with lethal and non lethal phenotype: a proteomic approach.

Authors:  Laura Bianchi; Assunta Gagliardi; Roberta Gioia; Roberta Besio; Chiara Tani; Claudia Landi; Maria Cipriano; Anna Gimigliano; Antonio Rossi; Joan C Marini; Antonella Forlino; Luca Bini
Journal:  J Proteomics       Date:  2012-02-18       Impact factor: 4.044

9.  Effects of tissue hydration on nanoscale structural morphology and mechanics of individual Type I collagen fibrils in the Brtl mouse model of Osteogenesis Imperfecta.

Authors:  Arika D Kemp; Chad C Harding; Wayne A Cabral; Joan C Marini; Joseph M Wallace
Journal:  J Struct Biol       Date:  2012-10-04       Impact factor: 2.867

10.  A method for the generation of conditional gene repair mutations in mice.

Authors:  I Dragatsis; S Zeitlin
Journal:  Nucleic Acids Res       Date:  2001-02-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.